| Cat. No. |
Product Name |
Information |
| PC-22202 |
JAK3 inhibitor RB1
JAK3 inhibitor
|
JAK3 inhibitor RB1 is a potent, selective and irreversible JAK3 inhibitor with IC50 of 40 nM, without inhibiting JAK1, JAK2 or TYK2 (IC50>5000 nM). |
| PC-21900 |
CEP-33779
JAK2 inhibitor
|
CEP-33779 is a potent, selective, and orally bioavailable inhibitor of JAK2 with IC50 of 1.3 nM, 65-fold selective over JAK-3. |
| PC-21596 |
JNJ-64251330
JAK inhibitor
|
Lorpucitinib (JNJ-64251330) is potent, selective and orally bioavailable pan-JAK inhibitor with IC50 of 0.37/8.6/92/7.4 nM for JAK1/JAK2/JAK3/Tyk2 respectively. |
| PC-21425 |
WHI-P131
JAK3 inhibitor
|
WHI-P131 (JANEX-1) is a potent and selective JAK3 inhibitor with Ki of 2.3 uM and IC50 of 78 uM, with no activity agianst JAK1 and JAK2. |
| PC-21281 |
QL-1200186
TYK2-JH2 inhibitor
|
QL-1200186 is a potent, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 0.06 nM, targets pseudokinase regulatory domain (Janus homology 2, JH2) of the TYK2 protein. |
| PC-21215 |
GDC-4379
JAK inhibitor
|
GDC-4379 is a potent, selective and inhaled JAK inhibitor, reduces FeNO and peripheral biomarkers of inflammation. |
| PC-20901 |
YLIU-5-162-1
JAK2 inhibitor
|
YLIU-4-105-1 is a novel type II JAK2 inhibitor, binds to JAK2 kinase domain (JH1), show potential for overcoming acquired resistance to ruxolitinib. |
| PC-20543 |
ABT-317
JAK1 inhibitor
|
ABT-317 (ABT317) is a potent, selective JAK1 inhibitor, inhibits IL-6-stimulated pSTAT3 (TF-1 cells, IC50=16 nM) and IL-2-stimulated pSTAT5 (T-blasts, IC50=30 nM). |
| PC-72038 |
NDI-031407
TYK2 inhibitor
|
NDI-031407 (NDI 031407) is a novel potent, selective TYK2 inhibitor with IC50 of 0.21 nM in radiometric assays, 20 fold selectivity over JAK3 (4.2 nM), 147 fold for JAK2 (31 nM), and 220 fold for JAK1 (46 nM). |
| PC-61277 |
EXEL-8232
|
A potent and selective, orally bioavailable JAK2 inhibitor with IC50 of 2 nM. |
| PC-45873 |
Ruxolitinib S enantiomer
|
The chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively.. |
| PC-45817 |
Tofacitinib citrate
|
A potent, specific, orally active inhibitor of JAK3 with IC50 of 1 nM in cell-free assays. |
